Medical Condition News

RSS

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

BSD Medical Corporation today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.

23 Apr 2010

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

The Society for Vascular Surgery published its first supplement on diversity articles to its Journal of Vascular Surgery in April 2010.

23 Apr 2010

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress.

23 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology to be held June 4-8, 2010 in Chicago, Illinois.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

A new Mayo Clinic study found that physical exercise and computer use may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.

23 Apr 2010

CRT teams up with The University of Auckland to discover novel treatments for cancer

Cancer Research Technology - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

First Edition: April 22, 2010

Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about the Money Follows The Person program: "Richard Hasselbach and Deborah Kadlec met in a nursing home and dreamed of a life together outside its walls. Their health conditions made living on their own a challenge: Hasselbach, 63, is disabled from a stroke and lost a leg to a blocked artery. Kadlec, 52, has multiple sclerosis. They both use wheelchairs and need help with chores such as bathing, cooking and remembering to take their medicines.

22 Apr 2010

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Barbara McCrady and Elizabeth Epstein wanted to know whether cognitive behavior therapy worked better for alcohol-dependent women when delivered as couples therapy than when delivered as individual therapy. They reported recently that both treatment methods worked well, but women treated in couples therapy maintained their gains a bit better than those in individual therapy. Also, women suffering from depression in addition to alcohol-dependence did better in couples therapy. Their paper appeared recently in the Journal of Consulting and Clinical Psychology.

22 Apr 2010

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.

22 Apr 2010

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs.

22 Apr 2010

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.

22 Apr 2010

New campaign highlights dangers of carrying excess weight around waist

Cancer Research UK has joined forces with the British Heart Foundation and Diabetes UK to launch a new campaign to raise awareness of the dangers of carrying excess weight around the waist.

22 Apr 2010

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI-PEG 20) to inhibit cancer cell growth.

22 Apr 2010

Medical Condition News

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

Tryton Medical widens European availability of Side Branch Stent System

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

FDA Advisory Committees vote against approval of Acurox NDA

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

CRT teams up with The University of Auckland to discover novel treatments for cancer

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

First Edition: April 22, 2010

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

New campaign highlights dangers of carrying excess weight around waist

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News